The impact of psychopharmacology on contemporary clinical psychiatry

Canadian Journal of Psychiatry

Volumn 59, Issue 8, 2014, Pages 412-416

  Vaźquez, Gustavo H ^a  

^a UNIVERSITY OF PALERMO   (Argentina)

Author keywords

Clinical psychiatry; Psychiatric diagnosis; Psychiatric treatments

Indexed keywords

NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; HIGH RISK BEHAVIOR; HUMAN; MENTAL DISEASE; META ANALYSIS (TOPIC); MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT SATISFACTION; POVERTY; PRACTICE GUIDELINE; PSYCHIATRY; PSYCHOPHARMACOLOGY; REVIEW; SUBSTANCE ABUSE;

CANADA; CHECKLIST; CLINICAL COMPETENCE; FORECASTING; GUIDELINE ADHERENCE; HUMANS; MENTAL DISORDERS; PHYSICIAN'S PRACTICE PATTERNS; PSYCHIATRY; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS; QUALITY ASSURANCE, HEALTH CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84905991149     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371405900803     Document Type: Review

References (34)

1. Craddock N, Mynors-Wallis L. Psychiatric diagnosis: impersonal, imperfect and important. Br J Psychiatry. 2014;204:93-95.
2. Gardner DM. Competent psychopharmacology. Can J Psychiatry. 2014;59(8):406-411.
3. Maddux JE, Winstead BA. Psychopathology: foundations for a contemporary understanding. Mahwah (NJ): Lawrence Erlbaum; 2005.
4. Cloninger CR. Implications of comorbidity for the classification of mental disorders: the need for a psychobiology of coherence. In: Maj M, Goebel W, Lopez-Ibor JJ, et al, editors. Psychiatric diagnosis and classification. Chichester (GB): Wiley; 2002. p 79-106.
5. Kapczinski F, Videira Dias V, Kauer-Sant'Anna M, et al. Potential use of biomarkers as an adjunctive tool for staging bipolar disorder. Progr Neuropsychopharmacol Biol Psychiatry. 2009;33:1366-1371.
6. Fava GA, Guidi J, Semprini F, et al. Clinical assessment of allostatic load and clinimetric criteria. Psychother Psychosom. 2010;79(5):280-284.
7. Lichtenberg P, Belmaker RH. Subtyping major depressive disorder. Psychother Psychosom. 2010;79(3):131-135.
8. Baldessarini RJ. Impact of psychopharmacology on contemporary psychiatry [guest editorial]. Can J Psychiatry. 2014;59(8):401-405.
9. Ösby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58(9):844-850. (Pubitemid 32979302)
10. Simon RI, Hales RE, editors. Textbook of suicide assessment and management. 2nd ed. Washington (DC): American Psychiatric Publishing; 2012.
11. Tondo L, Baldessarini RJ. Clinical management of suicidal risk. In: Yildiz A, Nemeroff C, Ruiz P, editors. Bipolar disorder. New York (NY): Oxford University Press; forthcoming 2014 Oct.
12. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225-235.
13. Cohen D, Bogers JP, van Dijk D, et al. Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J Clin Psychiatry. 2012;73(10):1307-1312.
14. Baldessarini RJ. Chemotherapy in psychiatry: the pharmacologic basis of treatments for major mental illness. 3rd ed. New York (NY): Springer Press; 2013.
15. Baldessarini RJ. American biological psychiatry and psychopharmacology 1944-1994. Chapter 16. In: Menninger RW, Nemiah JC, editors. American psychiatry after World War II (1944-1994). Washington (DC): American Psychiatric Press; 2000. p 371-412.
16. Bondy B. Genetics in psychiatry: are the promises met? World J Biol Psychiatry. 2011;12(2):81-88.
17. Farah MJ, Gillihan SJ. The puzzle of neuroimaging and psychiatric diagnosis: technology and nosology in an evolving discipline. AJOB Neurosci. 2012;3(4):1-11.
18. Linden DE. The challenges and promise of neuroimaging in psychiatry. Neuron. 2012;73(1):8-22.
19. Lehner T, Senthil G, Addington AM. Convergence of advances in genomics, team science, and repositories as drivers of progress in psychiatric genomics. Biol Psychiatry. 2014 Jan 15. pii: S0006-3223(14)00014-6. doi: 10.1016/j.biopsych.2014.01.003. [Epub ahead of print].
20. Dekel R, Drossman DA, Sperber AD. The use of psychotropic drugs in irritable bowel syndrome. Expert Opin Investig Drugs. 2013;22(3):329-339.
21. Mercier A, Auger-Aubin I, Lebeau JP, et al. Evidence of prescription of antidepressants for non-psychiatric conditions in primary care: analysis of guidelines and systematic reviews. BMC Fam Pract. 2013;4(5);14:55-65.
22. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2013;15:1-44.
23. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic agents: a critical overview. CMAJ. 2005;172:1703-1711. (Pubitemid 40896865)
24. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41.
25. Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318-378.
26. Vieta E, Pappadopulos E, Mandel FS, et al. Impact of geographical and cultural factors on clinical trials in acute mania: lessons from a ziprasidone and haloperidol placebo-controlled study. Int J Neuropsychopharmacol. 2011;14(8):1017-1027.
27. Vázquez GH, Baldessarini RJ, Yildiz A, et al. Multisite international collaborative trials in mania. Int J Neuropsychopharmacol. 2011;14(8):1013-1016.
28. Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252-260.
29. Song F, Parekh S, Hooper L, et al. Dissemination and publication of research findings: updated review of related biases. Health Technol Assess. 2010;14(8):1-193.
30. Turner EH. Publication bias, with a focus on psychiatry: causes and solutions. CNS Drugs. 2013;27(6):457-468.
31. Vázquez GH, Baldessarini RJ, Tondo L. Co-morbidity: bipolar and anxiety disorders: clinical and therapeutic overview. Depress Anxiety. 2014;31:196-206.
32. Thase ME. Antidepressant combinations: widely used, but far from empirically validated. Can J Psychiatry. 2011;56(6):317-323.
33. Farahani A, Correll CU. Are antipsychotics or antidepressants needed for psychotic depression? Systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. J Clin Psychiatry. 2012;73(4):486-496.
34. Jureidini J, Tonkin A, Jureidini E. Combination pharmacotherapy for psychiatric disorders in children and adolescents: prevalence, efficacy, risks and research needs. Paediatr Drugs. 2013;15(5):377-391.